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Abstract
Purpose The aim of this study is to evaluate the detection rate
of almotriptan, eletriptan, frovatriptan, sumatriptan,
rizatriptan, and zolmitriptan in the hair of migraineurs taking
these drugs; the degree of agreement between type of self-
reported triptan and triptan found in hair; if the concentrations
in hair were related to the reported cumulative doses of
triptans; and whether hair analysis was able to distinguish
occasional use from the overuse of these drugs.
Methods Out of 300 headache patients consecutively en-
rolled, we included 147 migraine patients who reported to
have taken at least one dose of one triptan in the previous
3 months; 51 % of the patients overused triptans. A detailed
pharmacological history and a sample of hair were collected
for each patient. Hair samples were analyzed by liquid
chromatography-electrospray tandem mass spectrometry
(LC-MS/MS) by a method that we developed.
Results All the triptans could be detected in the hair of the
patients. The agreement between type of self-reported triptan
and type of triptan found in hair was from fair to good for
frovatriptan and zolmitriptan and excellent for almotriptan,
eletriptan, sumatriptan, and rizatriptan (P < 0.01, Cohen’s
kappa). The correlation between the reported quantities of
triptan and hair concentrations was statistically significant
for almotriptan, eletriptan, rizatriptan, and sumatriptan
(P < 0.01, Spearman’s rank correlation coefficient). The accu-
racy of hair analysis in distinguishing occasionally users from
overusers was high for almotriptan (ROC AUC = 0.9092),
eletriptan (ROC AUC = 0.8721), rizatriptan (ROC
AUC = 0.9724), and sumatriptan (ROC AUC = 0.9583).
Conclusions Hair analysis can be a valuable system to dis-
criminate occasional use from triptan overuse.
Keywords Hair analysis . Monitoring .Migraine .
Medication-overuse headache . ROC curve . Triptan
Introduction
Migraine is a chronic disorder with recurrent attacks that af-
fects 10 % of the adult population [1]. The effective treatment
of attacks is fundamental to quickly relieve suffering and pre-
vent the progression toward chronic migraine [2]. Triptans,
selective agonists at 5-hydroxytryptamine 1B/1D (5-HT1B/
1D) receptor subtype, are recommended as first-line drugs for
the acute treatment of the attack in patients suffering from
moderate-severe migraine [3]. However, like every
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medication, triptans must be taken correctly to be effective.
Their use in clinical practice has instead revealed various
problems [4]. On the one hand, underuse both by episodic
[5] and chronic migraine [6] patients has often been reported
[7]. On the other hand, there is a large number of patients
overusing these medications, developing a type of
medication-overuse headache (MOH) [8, 9], defined as
Btriptan-overuse headache^ [10]. This chronic headache is
precisely due to Bregular intake of one or more triptans in any
formulations, on ten or more days per month for >3 months^
[10]. MOH is a serious, disabling, and difficult to treat disorder;
only the withdrawal of the overused medication can lead to an
improvement [9]. To face this situation, the ideal thingwould be
to be able to monitor triptan use [8]. To monitor drug use,
indirect or direct methods can be employed [11]. Indirect
methods, such as self-report and diaries, overestimate adher-
ence [12]. Direct methods, such as dosage of triptans in blood
and urine, are unfit, reflecting only recent drug intake.
In recent years, hair has become a fundamental biological
specimen to monitor adherence to pharmacological treatments
[13, 14] and document objectively the progress of detoxifica-
tion programs [15–17]. Hair analysis has a very wide window
of time of detection, which depends on the length of the hair;
therefore, you only need few samples to monitor a long peri-
od. In addition, hair analysis allows the clinician to distinguish
between occasional and chronic use [15, 17].
The aim of our study was to apply hair analysis to clinical
practice by a method that we validated [18], in order to eval-
uate the detection rate of triptans on the market in Italy in the
hair of migraine patients taking these drugs, the degree of
agreement between type of self-reported triptan and type of
triptan found in hair, whether the concentrations measured in
hair reflected the cumulative doses of triptans that the patients
had reported to have taken, and whether hair analysis was able
to distinguish occasional use from the overuse of these drugs.
Patients and methods
Patients
Of a total of 300 headache patients consecutively coming to
the Headache Centre of the University Hospital of Modena
(Italy), 147 patients (mean age ± SD: 45.29 ± 11.3 years, F
96%) who had reported to have used in the previous 3 months
at least one dose of one triptan by any way of administration
and whose hair in the nuchal area was at least 5 cm long, took
part in the study (all demographic data are available as
supplementary table). According to ICHD-3beta criteria
[10], they were divided into two groups: (1) with occasional
triptan use and (2) with triptan overuse (regular intake of one
or more triptans in any formulations, on ten or more days per
month for >3months). According to ICHD-3beta criteria [10],
all triptan overusers had been diagnosed with chronic mi-
graine. Among the patients taking triptans occasionally, 50
(70 %) had been diagnosed with migraine without aura, 12
(7 %) with chronic migraine, 5 (7 %) with migraine with and
without aura, and 4 (6 %) with migraine with aura. Seventy-
eight percent of the patients was between 25 and 55 years old.
All the patients had given their written consent to their
participation in the study. They were enrolled from October
1st, 2013 to December 23rd, 2014.
Procedures
For each patient, we collected by a specific form the
anagraphic data, diagnosis of headache, hair characteristics
(color and cosmetic treatments), and pharmacological history.
According to international guidelines for hair analysis [19], a
hair sample of at least 7 mm in diameter and 4 cm in length
was taken from each patient’s nuchal area. From each hair
sample, we cut and analyzed a single section measuring
3 cm, proximal, i.e., near the scalp, to cover the previous
3 months.
The concentrations of almotriptan, eletriptan, frovatriptan,
rizatriptan, sumatriptan, and zolmitriptan in hair samples were
determined by liquid chromatography-electrospray tandem
mass spectrometry (LC-MS/MS). The method had been de-
veloped by us and validated [18] according to the model pro-
posed by the Scientific World Group for Forensic Toxicology
in 2013, in Standard Practices for Method Validation in
Forensic Toxicology [19]. A number was assigned to each
hair sample. The laboratory made blind assessments.
Data analysis
A descriptive analysis and a comparison between triptan oc-
casional users and overusers were conducted as far as the
following aspects were concerned: demographic characteris-
tics, headache diagnosis, and pharmacological history.
The results of the detection of triptans in hair were then
compared to the patients’ self-report regarding the occasional
use or overuse of these drugs. The concentrations measured in
hair were considered positive expected if in agreement with
the self-reported occasional use or overuse of triptans; positive
unexpected if they were not in agreement with the self-
reported occasional use or overuse of triptans; negative
expected if the patient had taken at most four defined daily
doses (DDDs) of each triptan (almotriptan 50 mg, eletriptan
160 mg, frovatriptan 10 mg, sumatriptan 200 mg, rizatriptan
40 mg, and zolmitriptan 10 mg) in the previous 3 months; and
negative unexpected if the patient had taken more than four
DDDs of each triptan in the previous 3 months.
The agreement between the self-reported occasional use or
overuse of triptans and the concentrations measured in hair
had been assessed on the basis of previous data [18],
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considering that overuse was shown by levels >105 pg/mg for
almotriptan, >500 pg/mg for eletriptan, >4.5 pg/mg for
frovatriptan, >60 pg/mg for rizatriptan, >55 pg/mg for suma-
triptan, and >18 pg/mg for zolmitriptan. Unexpected results
and triptans found in hair, but not self-reported, were consid-
ered as signs of non-adherence by patients and excluded from
further statistical analysis.
Excluding results of non-adherent patients, we analyzed
the relationship between the cumulative doses and hair con-
centrations of each triptan and compared the mean cumulative
doses reported and the hair concentrations of each triptan be-
tween the two groups of patients. Finally, we determined the
accuracy of hair analysis in detecting triptan overusers and
cut-off hair concentrations to discriminate triptan overuser
from occasional user.
Statistical analysis
Statistical analysis was conducted by the StataIC 13 software.
The continuous variables normally distributed were expressed
as mean ± standard deviation and dichotomous variables were
indicated as percentage. The comparison between the means
was investigated by Student’s t test for independent data; to
compare binary variables, Chi-square test or one-sided
Fisher’s exact test was used when appropriate.
The relationship between two continuous variables was
analyzed by Spearman’s R correlation coefficient. The agree-
ment between the type of triptan reported by the patient and
the one detected by hair analysis was analyzed by Cohen’s K
coefficient. P < 0.05 was chosen as significant for all the tests.
The predictive accuracy of hair analysis was quantified by
the area under the curve (AUC) on receiver-operating charac-
teristic (ROC) curve analysis, the greater the area under the
curve the better hair analysis performs. The best cut-point
discriminating overusers from occasionally users were deter-
mined using the Liu’s method. Sensitivity, specificity, nega-
tive predictive value (NPV), and positive predictive value
(PPV) of hair analysis were determined at every cut-point
through ROC curve analysis.
Results
The vast majority (Table 1) of the analysis conducted on the
hair samples of the 147 patients who had declared to have
taken one or more triptans in the previous 3 months detected
measurable concentrations of each triptan reported by the pa-
tients, both by occasional users and overusers.
The agreement between the type of triptan self-reported
and type of triptan detected in hair, analyzed by Cohen’s kap-
pa, was statistically significant (P < 0.01) for each triptan,
excellent (kappa over 0.75) for almotriptan (kappa 0.88),
eletriptan (kappa 0.87), rizatriptan (kappa 0.94), and sumatrip-
tan (kappa 0.76), and fair to good (kappa from 0.40 to 0.75)
for frovatriptan (kappa 0.49) and zolmitriptan (kappa 0.72).
More than 70 % of almotriptan, eletriptan, and rizatriptan
hair concentrations (Table 2) were positive expected, i.e., in
agreement with the self-reported occasional use or overuse of
the triptan in the previous 3 months. Positive unexpected con-
centrations in comparison with the self-reported occasional
use or overuse of triptan were the minority. Unreported
triptans were only found in very few samples, in particular
rizatriptan and sumatriptan, each of which was found in 5
out of 147 patients (3.5 %), almotriptan, found in 4 patients
(3 %), and eletriptan, found in 3 (2 %) (scatterplots of all
analytical data are available as supplementary figure).
The agreement between the cumulative doses of each trip-
tan that the patients had reported to have taken in the previous
3 months, and their respective hair concentrations with
expected results was statistically significant for each triptan
(almotriptan: 0.79, eletriptan: 0.70, rizatriptan: 0.8, and suma-
triptan: 0.58; P < 0.01, Spearman’s rank correlation coeffi-
cient), except frovatriptan and zolmitriptan, because of the
very few cases.
Table 1 Positive results (triptan
detected) in hair analysis for each
triptan self-reported by 147
patients (since various patients
used more than 1 triptan, the
triptans reported were 176 in
total)
Triptan Number (%) of positive
occasional users in hair
test/number of self-reported
triptan users
Number (%) of positive
overusers in hair
test/number of self-reported
triptan users
Total number (%) of positive
results in hair test/total
number of self-reported
triptan users
Almotriptan 23/25 (92) 15/15 (100) 38/40 (95)
Eletriptan 12/15 (80) 29/31 (93.5) 41/46 (89)
Frovatriptan 1/10 (10) 3/5 (60) 4/15 (26.6)
Rizatriptan 20/20 (100) 8/8 (100) 28/28 (100)
Sumatriptan 11/18 (61) 20/22 (91) 31/40 (77.5)
Zolmitriptan 2/5 (40) 2/2 (100) 4/7 (57.1)
Total 69/93 (74) 77/83 (93) 146/176 (83)
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The analysis of each group’s results (Table 3) indicated that
in the previous 3 months, overusers had taken as an average
significantly higher cumulative doses of each triptan than oc-
casional users (P < 0.01, Student’s t test). Mean hair concen-
trations of each triptan in overusers were also significantly
higher, at least four times (P < 0.05, Student’s t test) compared
to occasional users, excepted for frovatriptan and zolmitriptan.
The 95 % CIs of average hair concentrations were very wide.
The largest area under the ROC curve (Fig. 1), indicating
excellent accuracy in correctly identifying triptan overusers,
was observed for rizatriptan; however, every ROC curve anal-
ysis showed a good accuracy of hair analysis in detecting
triptan overusers also for almotriptan, eletriptan, and sumatrip-
tan. In particular, at the cut-point for rizatriptan (Table 4), the
specificity was 100 % with a positive predictive value of
100 %.
Discussion
The results of our study (Table 1) showed that six triptans
could be determined in the hair of the patients who had occa-
sionally used or overused them to treat their migraine attacks
during the previous 3 months. As a whole, reported triptans
were detected in 83% of hair analyses. There was a substantial
concordance between the types of triptans reported by the
patients and those objectively detected by hair analysis. The
agreement between the type of self-reported triptan and the
one detected in hair was statistically significant (P < 0.01) and
more than fair to excellent for each of these drugs, according
to Cohen’s k values. In spite of this, the concordance between
self-report and hair analysis was incomplete as far as the cu-
mulative doses taken were concerned. Indeed, 29 % of hair
analyses (Table 2) gave unexpected results (both positive,
Table 2 Results of the comparison between hair concentration of each triptan and the self-reported occasional use or overuse of that triptan in the
previous 3 months
Results of hair analysis for every determined triptan
Results Almotriptan
n = 40 (%)
Eletriptan
n = 46 (%)
Frovatriptan
n = 15 (%)
Rizatriptan
n = 28 (%)
Sumatriptan
n = 40 (%)
Zolmitriptan
n = 7 (%)
Total n = 176
(%)
Positive
expected
30 (75) 35 (76) 3 (20) 20 (71) 23 (58) 2 (28.5) 113 (64)
Positive
unexpected
8 (20) 6 (13) 1 (7) 8 (29) 8 (20) 2 (28.5) 33 (19)
Negative
expected
2 (5) 3 (7) 2 (13) 0 (0) 5 (12) 0 (0) 12 (7)
Negative
unexpected
0 (0) 2 (4) 9 (60) 0 (0) 4 (10) 3 (43) 18 (10)
Table 3 Mean cumulative doses
(mg) that triptan occasional users
and overusers had reported to
have taken in the previous
3 months and respective mean
concentrations (pg/mg) in hair
(the 113 positive expected results
were analyzed)
Triptan Occasional users (n = 71)
Mean (95 % CI)
Overusers (n = 76)
Mean (95 % CI)
3-month cumulative
doses (mg)
Hair level
(pg/mg)
3-month cumulative
doses (mg)
Hair level
(pg/mg)
Almotriptan 113.75 **
66.19÷161.31
165.55 *
106.50÷224.60
1055
574.60÷1535.40
1306.5
176.14÷2436.90
Eletriptan 453.33 **
274.05÷632.62
371 **
161.23÷558.77
3447.69
2245.74÷4649.65
2470.73
1760.39÷3181.07
Frovatriptan 29.16 **
13.79÷44.54
0.56
−0.73÷1.84
137.91
105.81÷170.02
4.25
−1.16÷9.66
Rizatriptan 43.08 *
24.55÷61.60
20.62 *
9.28÷31.95
925.71
47.96÷1803.47
541.29
75.36÷1007.21
Sumatriptan 826.73 **
454.04÷1199.42
83.18 **
17.34÷149.03
7919.17
3421.15÷12,417.18
352.92
160.29÷545.54
Zolmitriptan 26.5 **
−3.32÷56.32
18.6
−21.73÷58.93
1087.5
−2247.88÷4422.88
26
−37.53÷ 89.53
Occasional users vs. overusers: 3-month cumulative doses and hair level, *P < 0.05; **P < 0.01, Student’s t test
for unpaired data
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19 %, and negative, 10 %), i.e., inadequate with the self-
reported occasional use or overuse of the triptan.
Furthermore, unreported triptans were detected in few sam-
ples. These results, considered as signs of non-adherence, are
consistent with those of other studies, which found out ap-
proximately or more than 35 % of non-adherence to pharma-
cological treatments in migraine patients [2, 7, 20].
Triptans have an indolic structure, are mainly basic, and
have a large distribution volume and a certain lipophilicity
[21]. All these characteristics allow their penetration into the
systemic circulation of growing hair, where the pH is acid
(approximately 4) [17], and their accumulation in the keratin
matrix. Hair analysis, traditionally used in the forensic field
[22], is more and more used in clinical medicine and research
for drug monitoring with undoubted advantages [13, 14, 17],
among which the possibility to determine the concentrations
of more drugs simultaneously. This opportunity is particularly
useful for migraine patients, who often take various types of
medications to treat acute attacks. With the method that we
developed [18], it was possible to determine the concentra-
tions of each of the six triptans simultaneously in the same hair
sample.
In normal clinical practice, the physician formulates the
diagnosis of MOH and proposes the treatment according to
what the patient reports or records in his/her diary, without
having an objective datum about drug overuse. By the analy-
sis of a single hair sample of 4 cm, we were able to prove
objectively the intake of each triptan during the previous
3 months, which is precisely the reference period in order to
diagnose medication-overuse headache, according to the
ICHD-3 beta classification [10]. Measuring in blood or urine
has instead a short surveillance window: it shows at most the
previous 2–3 days. With these matrixes, we would have need-
ed a very large number of samples for each individual patient
to monitor 3 months, causing an unacceptable trouble to the
patients.
The ICHD-3 beta classification [10] defines overuse in
terms of frequency, and regularity of use during at least
3 months. By hair analysis, it was possible to translate the
cumulative doses taken by the patients into measurable con-
centrations in the keratin matrix. Both the cumulative doses of
triptans taken (Table 3) and hair average concentrations were
significantly higher (P < 0.05, Student’s t test) in overusers
than in occasional users. It does not therefore seem to exist a
process of saturation of the absorption of triptans in the keratin
matrix.
Approximately, half the patients of our sample used
triptans to treat their migraine attacks occasionally. By hair
analysis, we also detected the concentrations of each triptan
which were associated with this appropriate use. With
Fig. 1 Receiver operator
characteristic (ROC) curve for
almotriptan, eletriptan, rizatriptan,
and sumatriptan
Table 4 Cut-points of hair
concentration to distinguish
occasional from triptan overusers
calculated by Liu method applied
to ROC curve analysis
Triptan Cut-point
(ng/mg)
Sensitivity
(%)
Specificity
(%)
Positive predictive
value (PPV) (%)
Negative predictive
value (NPV) (%)
Almotriptan 526 77 96 91 89
Eletriptan 789 82 82 91 75
Rizatriptan 179 86 100 100 97
Sumatriptan 139 83 96 90 89
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traditional matrixes, this would have been impossible, because
these medications are present for a short time in blood and
urine after intake [23]. They have a plasma half-life which
goes from 2–3 h for sumatriptan, rizatriptan, and zolmitriptan,
to 4–5 h for eletriptan; only frovatriptan has a plasma half-life
of 25 h [21].
The kinetics of orally administered triptans has a significant
interindividual variability, depending on various factors such
as reduced and erratic absorption during the migraine attack
and variations according to sex and metabolism [24]. When
determining hair concentrations of triptans taken orally, more
variability factors add, such as cosmetic hair treatment, hair
color, or melanin [17], which can have influenced the trapping
of triptans in the keratin matrix. As a matter of fact, the con-
fidence intervals of average triptan concentrations in hair
(Table 3) were very wide, both for occasional users and
overusers. All triptans have the same mechanism of action.
The main differences concern pharmacokinetics and metabo-
lism [24]. Precisely, these differences, together with the dif-
ferent lipophilicity and pKa value, are reflected in large dif-
ferences of concentrations found in hair between a triptan and
another. In fact, drugs penetration in hair depends on their pKa
values and polarity. The lower lipophilicity, the lower incor-
poration into hair and high pKa values increase the drug mel-
anin binding [17]. In fact, even with roughly similar cumula-
tive doses, hair concentrations of eletriptan, the triptan consid-
ered the most lipophilic of all, are much higher than those of
the less lipophilic sumatriptan and with low oral bioavailabil-
ity, of around 14 % [21].
Considering only adherent-patients, there was a statistically
significant relationship (P < 0.01) between the cumulative
doses taken and the concentrations in hair for each triptan
(when the number of cases was adequate). A relationship be-
tween doses and hair concentrations has also been described
for carbamazepine [25], antiretrovirals [14, 26], and imatinib
[27] and it represents a key characteristic for the use of hair
analysis in therapeutic drug monitoring.
Our study has some limits. It was a sample with a wide
female prevalence, partly because of female prevalence in
migraine and even more in chronic migraine associated to
drug overuse [9], from which suffered approximately 50 %
of the patients enrolled. In spite of this, we do not have any
elements to suppose significant differences between female
and male subjects in the penetration of triptans into hair. The
sample was deliberately heterogeneous for the type of triptans
used, the frequency of use, and the presence of outpatients and
inpatients, in order to assess the applicability of hair analysis
in the most different clinical conditions. All the patients only
took the medications orally. However, oral intake is the favor-
ite modality and the most used by the majority of migraine
patients [9]. As far as we know, the present study is the first to
compare self-reported triptan taking and triptan concentrations
in hair, so we cannot compare it to others. As a precaution, we
have therefore considered as expected the negative results of
the few patients who had taken less than four DDDs of each
triptan in the previous 3 months. The choice of four DDDS for
3-month period was arbitrary in the absence of other standard
references and more sensitivity analyses will serve to support
it.
Adherence to triptan prescriptions is fundamental to get
their therapeutic benefit [2]. Patients using triptans should
therefore be checked every 3–6 months [8]. Our results sug-
gest that hair analysis can be a valuable system to monitor the
use of triptans. In fact, hair analysis accuracy in detecting
triptan overuse (Fig. 1) was excellent for almotriptan,
rizatriptan, and sumatriptan, and was good for eletriptan.
The cut-point concentrations (Table 4) better discriminating
occasional users from overusers were associated with high
positive predictive values, indicating that a false positive result
is rare.
In conclusion, hair analysis is a unique approach to monitor
prescription triptan adherence according to the recommended
procedure to check migraine patients every 3–6 months [3, 8].
Moreover, the determination of triptan concentrations in hair
could be useful to make the response to prophylaxis objective
in clinical trials.
We hope that our findings can pave the way for future
research and application of hair analysis for the monitoring
of triptan use/adherence in migraine management.
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